Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares OutstandingShort-Term Debt repayments
Ratios

China Pharma Holdings (CPHI) Other Gross PP&E Adjustments (2016 - 2025)

Historic Other Gross PP&E Adjustments for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $37.3 million.

  • China Pharma Holdings' Other Gross PP&E Adjustments fell 154.11% to $37.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.3 million, marking a year-over-year decrease of 154.11%. This contributed to the annual value of $36.9 million for FY2024, which is 116.38% down from last year.
  • China Pharma Holdings' Other Gross PP&E Adjustments amounted to $37.3 million in Q3 2025, which was down 154.11% from $37.2 million recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Other Gross PP&E Adjustments peaked at $37.9 million during Q3 2024, and registered a low of -$25369.0 during Q1 2021.
  • Moreover, its 5-year median value for Other Gross PP&E Adjustments was $28.5 million (2022), whereas its average is $19.4 million.
  • Its Other Gross PP&E Adjustments has fluctuated over the past 5 years, first crashed by 10537.22% in 2021, then skyrocketed by 697833.98% in 2024.
  • Over the past 5 years, China Pharma Holdings' Other Gross PP&E Adjustments (Quarter) stood at $488309.0 in 2021, then soared by 5733.46% to $28.5 million in 2022, then surged by 31.21% to $37.4 million in 2023, then fell by 1.16% to $36.9 million in 2024, then grew by 0.91% to $37.3 million in 2025.
  • Its Other Gross PP&E Adjustments was $37.3 million in Q3 2025, compared to $37.2 million in Q2 2025 and $37.1 million in Q1 2025.